Quick Takeaways:
- Equine Performance Labs published a peer-reviewed, multi-center clinical trial in Frontiers in Veterinary Science showing that a single injection of equicenta CTM delivered superior outcomes to clinician-selected standard of care in lame performance horses.
- The 138-horse study across eight US equine practices found equicenta CTM significantly improved pain, swelling, and lameness, nearly tripled the odds of returning to prior performance levels, enhanced owner-reported well-being, and reduced injection-related adverse events.
- The ready-to-use regenerative therapy achieved better clinical outcomes without harvesting or processing, highlighting its potential as a convenient, evidence-backed treatment option for equine lameness.
Why It Matters?
With 138 horses across eight practices showing significantly better outcomes and nearly triple the odds of returning to prior performance, the data should help veterinarians justify using equicenta CTM as a convenient, regenerative alternative to harvesting/processing biologics or relying solely on conventional therapies. That can support adoption in sport and performance segments, strengthen the brand’s clinical credibility, and potentially expand its share in the equine musculoskeletal market where return-to-work speed and durability are key purchasing drivers.
Source: Businesswire
